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Abstract
Introduction: Systemic lupus erythematosus (SLE) is characterized by B cell hyper-activation and auto-reactivity 
resulting in pathogenic auto-antibody generation. The phenotypic analysis of blood B cell subsets can be used to 
understand these alterations.
Methods: The combined detection of CD19, CD27 and IgD (or IgM) by flow cytometry (FC) analysis delineates five 
well-defined blood B cell-subsets: naive, switched (S) memory, double negative (DN) memory and CD27 IgD IgM (non-
switched memory) B lymphocytes, and plasma cells (PCs). This phenotypic study was performed in 69 consecutive SLE 
patients and 31 healthy controls.
Results: SLE patients exhibited several abnormalities in the distribution of these B cell subsets, including elevated 
levels of DN memory B cells and PCs, and decreased CD27 IgD IgM B cells. Active SLE patients also showed decreased 
presence of S memory B cells and increased proportions of naive B lymphocytes. Nevertheless, when the patients in 
remission who did not require treatment were studied separately, the only remaining abnormality was a reduction of 
the CD27 IgD IgM B cell-subset detectable in most of these patients. The level of reduction of CD27 IgD IgM B cells was 
associated with elevated values of serum SLE auto-antibodies. Further analysis of this latter B cell-subset specifically 
showed increased expression of CD80, CD86, CD95, 9G4 idiotype and functional CXCR3 and CXCR4.
Conclusions: The presence of a reduced blood CD27 IgD IgM B cell-subset, exhibiting an activated state and enriched 
for auto-reactivity, is a consistent B cell abnormality in SLE. These findings suggest that CD27 IgD IgM B lymphocytes 
play a role in the pathogenesis of this disease.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disorder with heterogeneous clinical manifestations char-
acterized by B lymphocyte hyper-reactivity and forma-
tion of pathogenic auto-antibodies (Ab). The nature of
the immune alterations causing this disease remains elu-
sive. The occurrence of marked B cell activation and
auto-reactivity leads to consideration that one, or more,
of the physiological checkpoints controlling the self-anti-
gen recognizing B cell receptor (BCR) repertoire, and the
triggering and maturation of B lymphocytes, might be
affected [1]. In an attempt to gain a deeper knowledge on
the patho-physiology of human SLE, blood B lymphocyte
subsets have been extensively explored. In this regard,
when blood B cells are stained with labeled-monoclonal
Ab (mAb) anti-CD19, -CD27 and -IgD (or -IgM), and
analyzed by three-color flow cytometry (FC), five well-
defined B cell-subsets can be identified [2]; these are: 1)
naive B cells (CD19+ CD27- IgD+); 2) non-switched
memory B cells, also termed CD27 IgD IgM B cells
(CD19+ CD27+ IgD+); 3) conventional or switched (S)
memory B cells (CD19+ CD27+ IgD-); 4) a small propor-
tion of double negative (DN) memory B cells (CD19+
CD27- IgD-); and 5) plasma cells (CD19+ CD27++ IgD-).
From a comparison of these circulating B cell-subsets
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between healthy controls and SLE patients, the existence
of several B cell alterations in this disease has been deter-
mined. These alterations include B cell lymphopenia,
increased proportion of plasma cells (PC) and DN mem-
ory B cells, decreased naive B lymphocytes and, more
recently, decreased CD27 IgD IgM B cells [3-7]. The pres-
ent study reveals that a marked decrease of this latter B
cell-subset is a consistent and permanent blood B cell
aberration in SLE patients. Further results indicate that
this circulating cell-subset is enriched for cells exhibiting
auto-reactivity and activation features.
Materials and methods
Patients and control populations
Heparinized blood samples (10 ml) were obtained from
31 normal healthy donors (16 women and 15 men; mean
age 40 ± 2 years (range 26 to 59)) and 69 consecutive SLE
patients (63 women and 6 men; mean age 43 ± 2 years
(range 19 to 77)), who fulfilled the American College of
Rheumatology criteria for SLE. Disease activity was
defined by the SLE Disease Activity Index (SLEDAI).
Treatments received by the patients and SLEDAI score at
the time of analysis are shown in Table 1.
Patients 9, 17, 25, 29, 32, 38, 41, 43, 45, 46, 50, 53, 61, 64
and 68 had not received any treatment during a period of,
at least, three months before the analysis. The sample
from patient 29 was obtained just before she received
cyclophosphamide bolus therapy and, consequently, her
results are not included in the untreated group. Patients
and healthy donors were informed of the objective of the
study and gave their consent according to the Declaration
of Helsinki. Approval for this study was obtained from
the Institutional Review Board. (Comité Ético, Hospital
Universitario Puerta del Mar).
Preparation of peripheral blood mononuclear cells (PBMC) 
and FC analysis
PBMC were obtained from freshly-drawn blood by Ficoll-
Hypaque (Amersham Pharmacia Biotech, Uppsala, Swe-
den) density gradient centrifugation. Four-colour FC
analysis was performed by staining the cells with the fol-
lowing mAbs: peridinin chlorophyll protein-Cy5.5
(PerCP-Cy5.5)-labelled anti-CD19 (clone SJ25C1); allo-
phycocyanin (APC)-labelled anti-CD27; phycoerythrin
(PE)-labelled anti-CD95, -IgM, -CXCR3, -CXCR4, -CD49
d, -CD54, -CD62L, -CD80, -CD20, -CD22, -TACI and -
CD35; fluorescein isothiocyanate (FITC)-anti-rat IgG1/
2a (clone G28-5) and appropriate labelled-antibodies
used as negative controls (Becton Dickinson; San Jose,
CA, USA); PE and FITC-labelled anti-IgD (Dako, Ham-
burg, Germany), and PE-labelled anti-CD86, -CD50, -
CD21 (Beckman Coulter; Fullerton, CA, USA). 9G4 rat
mAb was a generous gift by Professor F Stevenson
(Southampton University Hospitals Trust, UK). Incuba-
tion of the cells (106 PBMC/100 μl of phosphate buffer
saline (PBS)) with mAbs was performed at room temper-
ature for 15 minutes. FC analysis was performed with a
FACSCalibur cytometer using CellQuest software (Bec-
ton Dickinson; San Jose, CA, USA). At least 20,000
CD19+ cells were collected for each analysis.
Chemotaxis assays
Chemotaxis to several chemokines of CD27 IgD IgM B
cells from control and SLE individuals was determined as
previously described [8]. Briefly, chemotaxis assays were
carried out in 24-well plates with transwell inserts (5-μm
pore size; Costar Corning, Corning, NY, USA). RPMI
1640 medium supplemented with BSA 0.5% was used as
assay medium. PBMCs were diluted in medium at a con-
centration of 10 × 106  cells/mL. The lower transwell
chamber was filled with 600 μL of medium either alone
(control) or containing 1 μg/mL of CXCL12 (SDF-1α),
CXCL10 (IP-10) or CCL3 (MIP-1α) (PeproTech, London,
UK), and then 100 μL of the cell suspension was added to
the upper chamber. Cells were allowed to migrate for four
hours at 37°C. Finally, the cells were collected from the
lower chamber and were stained and quantified by FACS.
The total number of migrated CD19+ CD27+ IgD+ B
cells was evaluated. Specific migration was calculated as
the number of cells that migrated in response to the stim-
uli divided by the number of cells that migrated in
response to medium (migration index).
Autoantibody detection
Anti-nuclear antibodies (ANA) were determined in
patients' serum samples obtained at the moment of the
study using indirect immunofluorescence (IIF) on HEp-2
cells. Anti-dsDNA Ab were measured by ELISA (AESKU-
LISA dsDNA G, AESKU DIAGNOSTICS, Wendelsheim,
Germany). Several nuclear specificities including U1-
RNP, Sm, Ro/SSA (52 and 60 kDa proteins), La/SSB, Scl-
70 topoisomerase-I, Ribosomal P-proteins and CENP-B
were detected by immunodot (INNO-LIA ana, INNO-
GENETICS, Ghent, Belgium).
Statistical methods
Differences between groups were analyzed with the Stu-
dent's t test and Mann-Whitney test. Comparison of data
included in Figure 1C was performed by ANOVA testing,
followed by Tukey's post-hoc analysis for pairwise com-
parisons. P-values lower than 0.05 were considered statis-
tically significant.
Results
Blood B cell-subsets alterations in SLE patients
Blood B cells, including PCs, can be identified as CD19+
cells [2]. The absolute number of blood B cells (CD19+
cells) in the present group of SLE patients was signifi-Rodríguez-Bayona et al. Arthritis Research & Therapy 2010, 12:R108
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Table 1: Treatments received by the patients and SLEDAI score at the time of analysis
Patient characteristics
Patient Sex Daily prednisone dose* Other treatment SLEDAI** %CD27+IgD+
1F L O W H C Q 4 7
2F M E D I U M C Y C 1 6 9
3F H I G H - 8 1
4F L O W - 4 3
5F - H C Q 2 7
6F L O W - 1 5 3
7F - H C Q 0 4
8F H I G H A Z A 1 0 5
9F - - 0 8
10 F - HCQ 0 11
11 F - HCQ 0 17
12 F LOW MMF 10 4
13 F HIGH AZA 1 3
14 F - HCQ 2 3
15 F MEDIUM HCQ 8 8
16 F HIGH HCQ 0 13
17 F - - 0 8
18 M LOW HCQ 4 12
19 F LOW HCQ 2 6
20 F LOW - 0 2
21 F MEDIUM HCQ 5 7
22 F HIGH HCQ 19 9
23 F LOW - 8 2
24 F LOW - 4 21
25 F - - 0 7
26 F LOW AZA 1 7
27 M LOW AZA 0 13
28 F - HCQ 0 18
29 F - - 11 6
30 F - HCQ 13 3
31 F LOW AZA 0 4
32 M - - 0 6
33 F - HCQ 4 8
34 F LOW HCQ 8 4
35 M HIGH - 8 6
36 F - HCQ 0 11
37 F - HCQ 0 25
38 F - - 3 8
39 F - HCQ 1 27
40 F - AZA/RX 0 2
41 F - - 0 24
42 F - HCQ 0 4
43 F - - 0 6Rodríguez-Bayona et al. Arthritis Research & Therapy 2010, 12:R108
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cantly lower than in normal subjects (82.0 ± 8.2 cells/μl
versus 144.7 ± 29 cells/μl, for SLE and healthy controls,
respectively; mean ± SEM; P  < 0.01). The additional
staining of these cells for surface CD27 and IgD mole-
cules, and the subsequent FC analysis, allows the distinc-
tion of five B cell-subsets. Figure 1A shows an example of
the phenotypic analysis of these blood B cell-subsets in a
control individual and in one SLE patient (FC dot plots),
and Figure 1B summarizes the results obtained from all
the SLE patients and the healthy controls. As can be seen,
SLE samples showed several alterations in the distribu-
tion of these B cell-subsets, including increased propor-
tions of DN memory B cells (CD27- IgD-) and PC
(CD27++ IgD-) and decreased CD27 IgD IgM B cells
(CD27+ IgD+); this latter finding was the most consis-
tent. The results for blood naive B cells (CD27- IgD+) and
S memory B cells (CD27+ IgD-) were similar in SLE
patients and controls.
Effect of disease activity and remission
The effect of disease activity on the described alterations
of the B cell-subsets was examined next. Accordingly, SLE
patients were distributed into two groups: one group con-
sisted of inactive and mildly active cases (SLEDAI range 0
to 5; 0.95 ± 0.2, mean ± SEM; N = 57); the second group
consisted of moderate to highly active patients (SLEDAI
range 8 to 19; 11.17 ± 1.09, mean ± SEM; N = 12). Figure
1C shows that both groups exhibited abnormally high fig-
ures of DN memory B cells and PC, but they differed in
that the more active SLE cases additionally showed signif-
icantly lower CD27 IgD IgM B cells and S memory B cells,
and abnormally high naive B cells.
The relevance of the described B cell-subset imbalances
during the course of the disease was then analyzed. To
this end, the group of SLE patients that remained in a
controlled and favorable phase of the disease, requiring
no treatment at the time of the study, was explored sepa-
44 F - MTX 0 8
45 F - - 0 13
46 F - - 0 28
47 F - HCQ 0 2
48 F LOW HCQ 0 16
49 F - HCQ 1 5
50 F - - 0 3
51 F - HCQ/MTX 0 8
52 F - HCQ 0 17
53 F - - 0 33
54 F - HCQ 0 6
55 F LOW MMF 4 15
56 F - HCQ 0 8
57 M - LFN 4 31
58 F - LFN 0 10
59 F LOW MTX 4 5
60 F LOW MTX 0 5
61 F - - 0 4
62 F - HCQ 1 7
63 F LOW MMF 0 15
64 F - - 0 3
65 F MEDIUM HCQ/MTX 2 2
66 M LOW - 0 13
67 F LOW - 0 13
68 F - - 0 17
69 F - AZA 1 4
*LOW (≤10 mg/day); MEDIUM (≤30 mg/day); HIGH (>30 mg/day).
AZA: azathioprine; HQC: hydroxychloroquine; CYC: cyclophosphamide; LFN: leflunomide MMF: mycophenolate mofetil; MTX: methotrexate; 
RX: rituximab; **SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.
Table 1: Treatments received by the patients and SLEDAI score at the time of analysis (Continued)Rodríguez-Bayona et al. Arthritis Research & Therapy 2010, 12:R108
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rately, and compared with the group of patients receiving
treatment. The clinical characteristics of the group of
untreated patients are depicted in Table 2.
Figure 1C shows that, the elevation of DN memory B
cells and PC proportions previously observed when all
the SLE cases were considered (Figure 1B), was normal-
ized in the group of untreated patients. In contrast, most
of the patients included in the untreated group (9 out of
14) still showed a decrease in the proportion of CD27 IgD
IgM B lymphocytes (Figure 1C), although, as a whole, the
Figure 1 Comparative analysis of blood B cell-subsets from SLE patients and healthy controls. CD19+ cells can be distributed into different B 
cell-subsets according to their additional expression of CD27 and IgD. A. Representative CD27-IgD dot plots from a control and a SLE patient indicating 
the distribution and percentages of these B cell-subsets: CD27-IgD+ (naïve), CD27+IgD- (S memory), CD27+IgD+ (CD27 IgD IgM), and CD27-IgD- (DN 
memory) B lymphocytes, and CD27highIgD- cells (PC). B. Scatter plots represent the percentages of these B cell-subsets in 31 controls (open circles) 
and 69 SLE patients (closed circles). The mean of each set of values is shown as a horizontal line. P values (Student's t test) are included. C. Scatter plots 
represent the percentage of each B cell-subset in controls and in SLE patients distributed according to disease activity (12 active and 57 inactive), and 
to the treatment (54 treated and 14 untreated). Symbols representing the control and the different SLE subgroups are displayed (bottom right panel). 
P values were calculated for the difference between the two pairs of SLE subgroups and between SLE subgroups and the control group. P values lower 
than 0.05 were considered statistically different (indicated as *).Rodríguez-Bayona et al. Arthritis Research & Therapy 2010, 12:R108
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difference between this group and the controls was non-
significant (Tukey's test, P = 0.09).
Correlation between blood CD27 IgD IgM B cells and serum 
SLE auto-Ab level
The relationship between the reduction of CD27 IgD IgM
B lymphocytes and the level of serum SLE auto-Ab was
also investigated in these patients. Accordingly, percent-
ages of CD27 IgD IgM B cells in SLE patients with nega-
tive/low levels (IIF titre ≤1/160) and medium/high levels
of ANA (IIF titre ≥1/320) (Figure 2A), positive and nega-
tive anti-dsDNA Ab (Figure 2B), and positive and nega-
tive anti-ENA (extractable nuclear antigens) Ab (Figure
2C), were determined. Figure 2 shows that higher levels
of ANA, anti-dsDNA and anti-ENA Ab were associated
with lower numbers of the B cell subset under study (Fig-
ure 2A, B and 2C, respectively).
Phenotypic and functional characteristics of SLE CD27 IgD 
IgM B lymphocytes
In an attempt to gain a deeper insight into this particular
B cell-subset, a broad phenotypic analysis was performed
on them, and the results obtained in SLE patients and
healthy controls were compared. The phenotype of nor-
mal CD27 IgD IgM B lymphocytes has been in part previ-
ously reported [2,9,10]. Figure 3A shows an example of
the histogram of expression of several B cell markers on
CD27 IgD IgM B cells, and Figure 3B summarizes the
results obtained in all the SLE and control blood samples
analyzed. The majority of SLE and control CD27 IgD IgM
B cells similarly expressed CD19, CD20, CD21, CD22,
CD35, CD49 d, CD50, CD54, CD62L and TACI (data not
shown) and surface IgM. In contrast, Figure 3A and 3B
show that SLE CD27 IgD IgM B cells expressed higher
levels of the co-stimulatory molecules CD80 and CD86,
the death receptor CD95, and the chemokine receptors
CXCR3 and CXCR4. Figure 3C also shows that the fre-
quency of 9G4+ cells detected in this B cell-subset was
clearly higher in SLE than in controls. This distinctive
pattern of molecule expression was equally detected in
CD27 IgD IgM B cells from patients with active disease or
in remission stage (data not shown). Interestingly, the
comparison of the same phenotypic study performed on
naive lymphocytes and DN and S memory B cells from
healthy controls and SLE patients revealed that, they were
appreciably similar, with the exception of a higher pro-
portion of CD95-expressing DN memory B cells in SLE
patients (Figure 4). Therefore, the observation of relevant
differences in phenotype between SLE and control blood
B cells was essentially restricted to the CD27 IgD IgM B
cell-subset. Finally, the functionality of increased CXCR4
and CXCR3 expression on CD27 IgD IgM B cells in SLE
patients was examined in a chemotaxis assay. As can be
seen in Figure 3D, CD27 IgD IgM B cells from healthy
controls and SLE patients migrated to the CXCR4 ligand
CXCL12, although these latter cells exhibited markedly
higher activity (P < 0.02). In addition, cells of healthy con-
trol and SLE patients also migrated to CXCL10, a ligand
of CXCR3. Again, the chemotactic activity of SLE CD27
IgD IgM B lymphocytes was higher, although, in this case,
the observed increase was not significant. SLE and
healthy control CD27 IgD IgM B cells did not express the
chemokine receptor CCR5 (data not shown) and, as
expected, no chemotaxis was observed when CCL3, a
ligand of CCR5, was tested.
Discussion
The present study demonstrates that the distribution of
blood B cell-subsets in SLE patients exhibits a variety of
alterations including elevated proportions of DN memory
B lymphocytes and PC, and decreased CD27 IgD IgM B
lymphocytes. In addition, active patients show decreased
S memory and increased naïve B lymphocytes, indicating
that patients in more active phases exhibit more abnor-
malities in the distribution of these B cell-subsets, and
these abnormalities are more pronounced. These data are
consistent with previous reports [3,5-7] and, taken
together, indicate that, in SLE patients, the B cell com-
partment undergoes profound alterations and imbalances
that are noticeable in the distribution of the normal B
cell-subsets present in the circulation. Moreover, the
results observed in the group of patients in remission
(untreated patients, Table 2) show that a decreased pro-
portion of CD27 IgD IgM B lymphocytes is the only B
cell-subset alteration persisting in the majority of these
cases. Serum SLE auto-Ab are relevant clinical parame-
ters in this disease. Present data reveal that the level of
elevation of these auto-Ab correlates with the intensity of
reduction of CD27 IgD IgM B lymphocytes in this dis-
ease. Further analysis indicates that CD27 IgD IgM B cells
from SLE patients exhibit higher expression of CD95,
CD80, CD86, CXCR3 and CXCR4. Chemotaxis assays
confirm that the increased expression of CXCR4 and
CXCR3 observed in SLE CD27 IgD IgM B cells is func-
tional, as the migration capacity to the appropriate
ligands exhibited by these lymphocytes is higher in SLE
patients' than in healthy controls. Increased CD95
expression has been previously reported in blood DN
memory B cells from SLE patients [11]. Present results
show that this observation can be also extended to CD27
IgD IgM B cell-subset (Figures 1 and 4). In addition,
increased expression of CD80 and CD86 in certain SLE
circulating B lymphocytes has been previously reported
[12], although the use of a B cell marker selection profile
different from that employed in the present study makes
the comparison of these results difficult. Present data are
consistent with the notion that the SLE patients' CD27
IgD IgM B cells distinctively are in an activated state,Rodríguez-Bayona et al. Arthritis Research & Therapy 2010, 12:R108
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exhibiting a potentially higher capacity to migrate and to
interact with T cells. Taken together, the present findings
indicate that a decreased proportion of blood CD27 IgD
IgM B lymphocytes appears to be an alteration that is
permanent in SLE patients, irrespective of disease activ-
ity; in addition, these cells exhibit an activated phenotype.
These observations suggest that CD27 IgD IgM B cell-
subset might play a role in the patho-physiology of SLE.
Previous studies have established that the repertoire of
mature naïve B lymphocytes is enriched for self-reactive
clones in SLE patients [13,14]. This observation indicates
that SLE patients exhibit defective B cell tolerance check-
p o i n t s  p r e s e n t  i n  n o r m a l  s u b j e c t s  [ 1 5 ]  a n d ,  i n  c o n s e -
quence, the emergence of an increased frequency of these
auto-reactive naive B cells is probably relevant in the
pathogenesis of SLE. However, a possible role of CD27
Table 2: Summary of clinical characteristics of the group of untreated patients
Patient number* P9 P17 P25 P32 P38 P41 P43 P45 P46 P50 P53 P61 P64 P68
S e x F FFMFFFFFFFFFF
CD27+IgD+ (%) 88 7 6 82 461 3 2 833 34 31 7
SLEDAI** score 0 0003000000000
SLICC*** score 0 0101210050010
Disease manifestations****:
Joint x xxx xxxx xxxx
Mucocutaneous x xxxx x x x x
CNS involvement xx
Renal involvement xxx
Hematologic x
Serositis xx
(*) Patients' numbers are the same as in Table 1. (**) SLEDAI, Systemic Lupus Erythematosus Disease Activity Index. (***) SLICC, "Systemic Lupus 
International Collaborating Clinics" damage index for SLE. Except where indicated otherwise, data were obtained at the moment of the inclusion 
into the study. (****) The clinical manifestations that appeared throughout the course of the disease are shown.
CNS: central nervous system
Figure 2 Comparative analysis of blood CD27 IgD IgM B cell-subsets from healthy controls and different groups of SLE patients according 
to the presence of autoantibodies. A. B cell subsets from healthy controls (n = 31) and SLE patients with negative or low levels (IIF titre ≤1/160; n = 
23) and medium or high levels (IFF titre ≥1/320; n = 46) of ANA were compared. B and C. Comparison among healthy controls and SLE patients with 
anti-dsDNA negative (n = 46) or positive (n = 23) and anti-ENA negative (n = 41) or positive (n = 28) Ab, respectively. Differences between groups are 
indicated (* P < 0.05; ** P < 0.01).Rodríguez-Bayona et al. Arthritis Research & Therapy 2010, 12:R108
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IgD IgM B lymphocytes in the state of auto-reactivity
characteristic of this disease has been less studied. This
is, at least in part, due to the fact that the origin, nature
and functional significance of normal CD27 IgD IgM B
cells remain subject of debate [7,9,10]. These lympho-
cytes were defined as non-switched (IgM+ IgD+) mem-
ory B cells based on the findings that they express the
putatively memory B cell marker CD27 [2], and harbor
IGV  genes exhibiting a low but detectable number of
somatic mutations, an event classically restricted to post-
germinal center (GC) memory B cells [2,9]. Nevertheless,
the observation of normal quantities of mutated CD27
Figure 3 Comparative phenotypic analysis of blood CD27 IgD IgM B cell-subsets (CD27+IgD+) from controls and SLE patients. This B cell-
subset was examined for the surface expression of different molecules. A. Representative histograms depict the expression of IgM, CD80, CD86, 
CXCR3, CXCR4 and CD95 for a healthy control and a SLE patient. For each baseline plot, negative isotypic antibody controls are superimposed in dot-
ted lines. B. Bar histograms show the percentages of positive CD27+IgD+ B cells (upper) and the mean fluorescence intensity (lower) for each marker 
in healthy controls (N = 10; open bars) and SLE patients (N = 10; grey bars). C. Expression of 9G4 idiotype in healthy controls (N = 6) and SLE patients 
(N = 22) is shown. A representative histogram is shown. Results represent the mean ± SEM. P values were calculated using the Mann-Whitney test. P 
values lower than 0.05 were considered statistically different (marked with an asterisk). D. A comparison is shown of the chemotaxis of CD27 IgD IgM 
B cells from healthy controls and SLE patients induced by CXCL12, CXCL10 and CCL3. Migration in the absence of stimuli is represented as a dotted 
line. Results are expressed as a migration index and represent the mean ± SEM (N = 4). P-values were calculated using the Mann-Whitney test. P < 0.05 
was considered statistically significant. Asterisks represent significant differences between healthy controls and SLE patients. Hashes indicate signifi-
cant differences in chemokine-induced migration with respect to medium alone.Rodríguez-Bayona et al. Arthritis Research & Therapy 2010, 12:R108
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IgD IgM B lymphocytes in immunodeficient patients that
lack GC formation and conventional switched memory B
cells, indicates that the generation of the cell-subset
under study can be GC-independent; hence, the IGV
gene somatic mutations present in this B cell-subset are
thought to represent a pre-immune diversification pro-
cess [9,16]. Human CD27 IgD IgM B lymphocytes have
been associated with the spleen marginal zone, and they
appear to be involved in the production of natural anti-
bodies [9,16]. The mechanisms that determine the
somatic mutations occurring in CD27 IgD IgM B cells
remain to be clarified, although it has been recently
shown that this B cell subset can express activation-
induced cytidine deaminase (AID), either during a tran-
sient post-natal phase [17], or upon Toll Like Receptors
(TLR)-engagement [18]. Under this latter condition,
CD27 IgD IgM B cells are capable of differentiating into
IgG-secreting plasma cells [18]. Interestingly, normal
human CD27 IgD IgM B lymphocytes exhibit a frequency
of auto-reactive BCR much lower than that observed in
naive B lymphocytes, suggesting that an additional check-
point for preventing self-reactivity exists at this level [19].
In this context, it is reasonable to think that a failure of
this BCR control process would necessarily lead to the
emergence within this B cell-subset of auto-reactive
clones. It is well-established that the immunoglobulin (Ig)
idiotype recognized by the 9G4 mAb is enriched in auto-
reactive B cell populations, including anti-DNA Ab-bear-
ing B cells occurring in SLE patients [20]. Accordingly,
the presence of B lymphocytes containing the 9G4 idio-
type in their surface Ig was examined in the blood CD27
IgD IgM cell-subset. Present data reveal that the fre-
quency of 9G4+ cells detected in this B cell-subset was,
on average, five times higher in SLE than in controls. This
result indicates that SLE patients show a defective control
on the appearance of auto-reactive clones within the cir-
culating CD27 IgD IgM B cell-subset. The cause of this
failure remains unknown. It is conceivable that these
auto-reactive cells, after appropriate self-antigen recogni-
tion, maybe in combination with TLR-activation [18],
would undergo activation and migration toward lym-
phoid tissue where they could progress into further dif-
ferentiation, giving rise to auto-reactive switched
memory B cells and PCs. This explanation is consistent
with the findings reported here. Thus, a permanent
decrease of circulating CD27 IgD IgM B cells could be the
result of self-antigen activation of auto-reactive B cells
contained in elevated proportions in this subset, and their
subsequent recruitment into lymphoid tissues. In fact,
9G4+ activated B cells and PCs have previously been
detected in lymphoid tissues (spleen, tonsil GC and bone
marrow) from SLE patients, but not from normal subjects
[21]. In conclusion, CD27 IgD IgM B lymphocytes might
play a role in the complex B cell alteration causing SLE.
Figure 4 Comparative phenotypic analysis of different blood B cell-subsets from controls and SLE patients. Indicated B cell-subsets were ex-
amined for the surface expression of several molecules including CD80, CD86, CXCR3, CXCR4, CD95 and 9G4. Bar histograms show the percentages 
of positive B cells (mean ± SEM) for each marker in healthy controls (N = 10; open bars) and SLE patients (N = 10; grey bars). P values were calculated 
using the Mann-Whitney U test, and statistically significant p values are marked with an asterisk (P < 0.05).Rodríguez-Bayona et al. Arthritis Research & Therapy 2010, 12:R108
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Conclusions
This study shows that the presence of a reduced blood
CD27 IgD IgM B cell-subset, exhibiting an activated state,
an increased capability to migrate towards CXCR4 ligand
and enriched for auto-reactivity is a prominent B cell
abnormality in SLE. In addition, higher levels of ANA,
anti-dsDNA and anti-ENA Ab were associated with
lower numbers of CD27 IgD IgM B cells in SLE patients.
These findings suggest that CD27 IgD IgM B lympho-
cytes play a role in the pathogenesis of this disease.
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